About this trial
This study tests ways to help opioid treatment programs (OTPs) keep patients in care. Staying on methadone or buprenorphine is linked to better outcomes, yet many people leave treatment early. The project will compare two approaches that provide clinics with retention/outcome quality measures and a quality-improvement (QI) toolkit-either alone or with added facilitation-against usual care.
Forty-five BayMark OTPs in multiple states will be randomly assigned to one of three groups: (1) quality measures + QI toolkit; (2) quality measures + QI toolkit + external QI facilitation; or (3) usual care.
The primary outcome is 90-day retention in treatment, measured from OTP electronic health records and Medicaid claims. Secondary outcomes include emergency department visits, hospitalizations, overdoses, and mortality. Findings will identify practical, scalable strategies to improve patient retention in OTPs.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- Quality Measures (Audit and Feedback)
- Quality Improvement (QI) Toolkit
- External QI Facilitation
Treatment groups
Sponsors and collaborators
RTI International
Lead sponsor
University of California, Los Angeles
Collaborator
Los Angeles County Department of Public Health - Substance Abuse Prevention and Control (SAPC)
Collaborator
National Institute on Drug Abuse (NIDA)
Collaborator
BayMark Health Services
Collaborator